Skip to main content
Top
Published in: Supportive Care in Cancer 1/2013

01-01-2013 | Original Article

Laxative prescriptions to cancer outpatients receiving opioids: a study from the Norwegian prescription database

Authors: Lars Morten Skollerud, Olav MS. Fredheim, Kristian Svendsen, Svetlana Skurtveit, Petter C. Borchgrevink

Published in: Supportive Care in Cancer | Issue 1/2013

Login to get access

Abstract

Background

During opioid treatment of cancer pain, constipation is one of the most prevalent and bothersome side effects. Guidelines suggest that treatment with laxatives should be initiated when opioid therapy is started.

Aim

This study aims: (1) to determine to what extent patients, starting on opioids due to cancer pain, receive laxatives; (2) to examine the temporal relationship between initiation of opioid therapy and initiation of treatment with laxatives; and (3) to study to which extent the treatment follows current guidelines.

Methods

Data from the Norwegian prescription database (NorPD) were used to investigate dispensed prescriptions of laxatives to outpatients in Norway, who are receiving opioids for cancer pain. Data from NorPD cover all dispensed prescriptions of drugs to outpatients, making it possible to follow patients over time. The study cohort was followed from 2005 to the end of 2008.

Results

Of 2,982 patients who started opioid therapy directly with WHO step III opioids, 1,325 patients (44.4 %) did not receive laxatives during the study period. Only 738 patients (24.7 %) received laxatives at the same time as opioid therapy was initiated. Another 657 patients (22.0 %) received laxatives after their initiation of opioids at some time during the study period.

Conclusion

Of those who started directly on a strong opioid, only one fourth received laxatives concomitantly with the first opioid, and nearly half did not receive laxatives at all. These findings indicate that the current guidelines are not followed.
Appendix
Available only for authorised users
Literature
2.
go back to reference Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R (2009) The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 10:35–42PubMedCrossRef Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R (2009) The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 10:35–42PubMedCrossRef
3.
go back to reference Droney J, Ross J, Gretton S, Welsh K, Sato H, Riley J (2008) Constipation in cancer patients on morphine. Support Care Cancer 16:453–459PubMedCrossRef Droney J, Ross J, Gretton S, Welsh K, Sato H, Riley J (2008) Constipation in cancer patients on morphine. Support Care Cancer 16:453–459PubMedCrossRef
4.
go back to reference Fredheim OM, Skurtveit S, Breivik H, Borchgrevink PC (2009) Increasing use of opioids from 2004 to 2007—pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 14:289–294PubMedCrossRef Fredheim OM, Skurtveit S, Breivik H, Borchgrevink PC (2009) Increasing use of opioids from 2004 to 2007—pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 14:289–294PubMedCrossRef
5.
go back to reference Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587–593PubMedCrossRef Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587–593PubMedCrossRef
6.
go back to reference Holzer P (2007) Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs 16:181–194PubMedCrossRef Holzer P (2007) Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs 16:181–194PubMedCrossRef
7.
go back to reference Kurz A, Sessler DI (2003) Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63:649–671PubMedCrossRef Kurz A, Sessler DI (2003) Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63:649–671PubMedCrossRef
8.
go back to reference Laugsand EA, Kaasa S, de Conno F, Hanks G, Klepstad P (2009) Intensity and treatment of symptoms in 3,030 palliative care patients: a cross-sectional survey of the EAPC Research Network. J Opioid Manag 5:11–21PubMed Laugsand EA, Kaasa S, de Conno F, Hanks G, Klepstad P (2009) Intensity and treatment of symptoms in 3,030 palliative care patients: a cross-sectional survey of the EAPC Research Network. J Opioid Manag 5:11–21PubMed
9.
go back to reference Fallon M, Cherny NI, Hanks G (2010) Opioid analgesic therapy. In: Hanks GWC (ed) Oxford textbook of palliative medicine. Oxford University, Oxford, p 689 Fallon M, Cherny NI, Hanks G (2010) Opioid analgesic therapy. In: Hanks GWC (ed) Oxford textbook of palliative medicine. Oxford University, Oxford, p 689
10.
go back to reference Miles CL, Fellowes D, Goodman ML, Wilkinson S (2006) Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev (4):CD003448 Miles CL, Fellowes D, Goodman ML, Wilkinson S (2006) Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev (4):CD003448
11.
go back to reference Noguera A, Centeno C, Librada S, Nabal M (2010) Clinical use of oral laxatives in palliative care services in Spain. Support Care Cancer 18:1491–1494PubMedCrossRef Noguera A, Centeno C, Librada S, Nabal M (2010) Clinical use of oral laxatives in palliative care services in Spain. Support Care Cancer 18:1491–1494PubMedCrossRef
12.
go back to reference Pappagallo M (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:11S–18SPubMedCrossRef Pappagallo M (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:11S–18SPubMedCrossRef
13.
go back to reference Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B (1992) A long-term survey of morphine in cancer pain patients. J Pain Symptom Manag 7:259–266CrossRef Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B (1992) A long-term survey of morphine in cancer pain patients. J Pain Symptom Manag 7:259–266CrossRef
14.
go back to reference Skurtveit S, Furu K, Kaasa S, Borchgrevink PC (2009) Introduction of low dose transdermal buprenorphine—did it influence use of potentially addictive drugs in chronic non-malignant pain patients? Eur J Pain 13:949–953PubMedCrossRef Skurtveit S, Furu K, Kaasa S, Borchgrevink PC (2009) Introduction of low dose transdermal buprenorphine—did it influence use of potentially addictive drugs in chronic non-malignant pain patients? Eur J Pain 13:949–953PubMedCrossRef
15.
go back to reference Svendsen K, Borchgrevink P, Fredheim O, Hamunen K, Mellbye A, Dale O (2010) Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses 25(7):725–732 Svendsen K, Borchgrevink P, Fredheim O, Hamunen K, Mellbye A, Dale O (2010) Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses 25(7):725–732
16.
go back to reference Sykes NP (1998) The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12:375–382PubMedCrossRef Sykes NP (1998) The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12:375–382PubMedCrossRef
17.
go back to reference Wirz S, Klaschik E (2005) Management of constipation in palliative care patients undergoing opioid therapy: is polyethylene glycol an option? Am J Hosp Palliat Care 22:375–381PubMedCrossRef Wirz S, Klaschik E (2005) Management of constipation in palliative care patients undergoing opioid therapy: is polyethylene glycol an option? Am J Hosp Palliat Care 22:375–381PubMedCrossRef
18.
go back to reference World Health Organization (1996) Cancer pain relief: with a guide to opioid availability, 2nd ed. Geneva World Health Organization (1996) Cancer pain relief: with a guide to opioid availability, 2nd ed. Geneva
Metadata
Title
Laxative prescriptions to cancer outpatients receiving opioids: a study from the Norwegian prescription database
Authors
Lars Morten Skollerud
Olav MS. Fredheim
Kristian Svendsen
Svetlana Skurtveit
Petter C. Borchgrevink
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 1/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1494-8

Other articles of this Issue 1/2013

Supportive Care in Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine